TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego. The company develops small molecule multi-target kinase inhibitors and combines a focus on vascular biology with expertise in small molecule medicinal chemistry. TargeGen compounds are primarily designed to inhibit vascular permeability, vascular proliferation, and inflammation. These biological processes are common to the pathology of many major human diseases. TargeGen's current compound in clinical development is TG101348 for the treatment of myeloproliferative diseases. The company has additional compounds in development for the treatment of inflammatory and ocular diseases.
TargeGen Drug Discovery
TargeGen's proprietary compounds are designed using advanced rational design techniques aided by computational chemistry and modeling technologies. TargeGen discovery programs are primarily focused on the development of src-kinase, PI3K and Jak-2 inhibitors.
TargeGen Investors Include:
- Forward Ventures
- VantagePoint Venture Partners
- Enterprise Partners
- William Blair Capital Partners/Chicago Growth Partners
- CDP Capital
- BB BIOTECH VENTURES
- Hambrecht & Quist Capital Management
- Innovis Investments
- A.M. Pappas & Associates
- CTI Life Sciences Fund